Osteoarthritis is a chronic progressive disease where there is degeneration and loss of articular cartilage that occurs together with new bone formation at the joint surfaces and margins that causes pain and deformity.
The patient experiences pain, stiffness, decreased movement, inflammation and crepitus.
The pain is usually aggravated by pain and relieved by rest.
Treatment with subcutaneous tanezumab 5 mg yields significant improvements in pain, physical function and PGA-OA in patients with moderate-to-severe osteoarthritis (OA) who have not responded to or could not tolerate standard-of-care analgesics, according to the results of a phase III trial.
Short-term treatment (6 weeks) with 10 mg prednisolone effectively reduces finger pain and improves function in patients who have painful hand osteoarthritis (OA) coupled with signs of inflammation, the HOPE* study has shown.
Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).
In patients with symptomatic knee osteoarthritis (OA), the presence of knee chondrocalcinosis (CC) does not appear exert any influence on the risk of arthroplasty or disease progression at 5 years, according to a study.
The new selective cathepsin K inhibitor MIV-711 does not perform better than placebo in easing osteoarthritic pain, a study has shown. However, it substantially decreases bone and cartilage progression with a reassuring safety profile.
Radiofrequency ablation and neuromodulation modalities for knee osteoarthritis (OA) potentially improve pain, functionality and disease-specific quality of life for up to 3–12 months with minimal localized complications, according to the results of a systematic review.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.